Valerio Therapeutics
ALVIO
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.80 | 11.80 | -0.13% |
| CAC 40 | 8,046.70 | 71.85 | 0.90% |
| DAX 40 | 24,564.40 | 178.62 | 0.73% |
| Dow JONES (US) | 46,602.98 | 91.99 | -0.20% |
| FTSE 100 | 9,566.65 | 83.07 | 0.88% |
| HKSE | 26,829.46 | 128.31 | -0.48% |
| NASDAQ | 22,788.36 | 153.30 | -0.67% |
| Nikkei 225 | 47,734.99 | 215.89 | -0.45% |
| NZX 50 Index | 13,568.48 | 37.19 | 0.27% |
| S&P 500 | 6,714.59 | 25.69 | -0.38% |
| S&P/ASX 200 | 8,947.60 | 10.80 | -0.12% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |